| abstract |
The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the NRARP gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of a disease or disorder related to neovascularization characterised by increased expression and/or activity of NRARP gene, said eye condition is selected from the group comprising age-related macular degeneration (AMD), ischemic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), diabetic retina ischemia (DRI), diabetic retinal edema (DRE) and retinopathy of prematurity (ROP) and combinations thereof. |